Phase 2 Trial Testing Alkahest’s Investigational GRF6019 for Alzheimer’s Doses First Patient

Phase 2 Trial Testing Alkahest’s Investigational GRF6019 for Alzheimer’s Doses First Patient
Alkahest's Phase 2 clinical trial testing GRF6019 — an experimental blood-derived protein — in patients with mild to moderate Alzheimer's disease has dosed its first participant, the company recently announced. The trial (NCT03520998), which will assess the safety, tolerability, and feasibility of GRF6019, is still recruiting participants. Researchers expect to enroll 40 patients. "The initiation of this study represents a significant milestone for Alkahest, and reflects our commitment to developing innovative therapies to treat this devastating disease," Karoly Nikolich, president and CEO of Alkahest, said in a press release. Proteins in the circulatory system can directly affect motor and cognitive function. GRF6019 is a blood plasma-derived protein being developed by Alkahest in collaboration with Grifols to treat neurodegenerative disorders. The compound was found to improve age-related cognitive and motor decline in preclinical studies. Most importantly, the therapy is not restricted by blood type matching and is optimized for therapeutic uses. In a previous open-label clinical trial — the PLasma for Alzheimer SymptoM Amelioration (PLASMA) study (NCT02256306) — researchers found that repeat
Subscribe or to access all post and page content.